ReFacto is indicated for the control and prevention of hemorrhagic episodes and for surgical prophylaxis and for short-term routine prophylaxis to reduce the frequency of spontaneous bleeding episodes in patients with hemophilia A. The effect of regular routine prophylaxis on long-term morbidity and mortality is unknown.

ReFacto is a recombinant B-domain-deleted factor VIII with an albumin-free final formulation.16* ReFacto works by replacing factor VIII in people with hemophilia A, enabling their blood to clot. The Chinese hamster ovary cell line used to produce ReFacto is grown in culture medium that contains human serum albumin. Following purification, the albumin concentration is below the detection limit of the assay.

Tarceva monotherapy is indicated for the treatment of patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) after failure of at least one prior chemotherapy regimen. Results from two multicenter, placebo-controlled, randomized, Phase III trials conducted in first-line patients with locally advanced or metastatic NSCLC showed no clinical benefit with the concurrent administration of Tarceva with platinum-based chemotherapy, and its use is not recommended in that setting.

Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumor-induced hypercalcemia) in patients with advanced malignancies involving bone. ZOMETA is indicated for multiple myeloma and bone metastases in more than 60 countries, including the United States and the European Union.

The following is a partial list of conditions that have been determined to be acceptable indications for hyperbaric oxygen therapy by Medicare, the Undersea and Hyperbaric Medical Society (UHMS), and the American College of Hyperbaric Medicine (ACHM). It is very important to note that each organization has its own list of approved indications and the following list is a combination of those lists and not an approved list from any one organization listed here.

If a vaginal hysterectomy can be performed in the first place, there would be no point in adding the costs and complications of laparoscopy. Its greatest benefit is the potential to convert what would have been an abdominal hysterectomy into a vaginal hysterectomy. An abdominal hysterectomy requires both a vaginal incision and a four to six inch long incision in the abdomen, which is associated with greater post-operative discomfort and a longer recovery period than for a vaginal procedure.

ReFacto is indicated for the control and prevention of hemorrhagic episodes and for surgical prophylaxis and for short-term routine prophylaxis to reduce the frequency of spontaneous bleeding episodes in patients with hemophilia A. The effect of regular routine prophylaxis on long-term morbidity and mortality is unknown.

The remote possibility exists for hypersensitivity to non-human mammalian proteins. Known hypersensitivity to mouse or hamster proteins may be a contraindication to the use of ReFacto.

B-domain-deleted recombinant factor VIII (BDDrFVIII) gene inserted into production cell (Chinese hamster ovary cells) ReFacto is filtered away from production cells and then purified and concentrated by a chromatography step Using recombinant technology, the gene for human factor VIII is identified, the B-domain deleted, and the gene inserted into special production cells (Chinese hamster ovary [CHO] cells).

Dosage and duration of treatment with ReFacto depend on the severity of the factor VIII deficiency, the location and extent of the bleeding, and the patient's clinical condition. Please see the Dosing and Administration section of the Prescribing Information for complete information. Doses administered should be titrated to the patient's clinical response.

Each ReFacto carton holds a single-use vial containing either 250, 500, 1000, or 2000 IU of product; a prefilled diluent syringe; a vial adapter; a sterile infusion set; and 2 alcohol swabs. ReFacto introduced the convenience device called R2 (Rapid Reconstitution) in November 2004. Click here to obtain more information about the R2 Kit and how it is supplied.

ReFacto is administered by intravenous infusion after reconstitution with sterile diluent. For ease of reconstitution and administration, ReFacto requires only 4 mL of diluent for all vial potencies.16 Prolonged exposure of the ReFacto vial to light should be avoided during storage. Freezing should be avoided to prevent damage to the diluent vial. Because ReFacto does not contain a preservative, it should be administered within 3 hours after reconstitution.

Spas in Karlovy Vary and Marienbad specialize mostly in treatment of digestive and metabolic disorders. Infectious diseases, serious heart diseases, acute thrombophlebitis, inflammatory rheumatic diseases in an acute state, tumor diseases with metastasis, acute psychosis, labile diabetes with reoccurring acidosis, pregnancy, alcohol or other substances addiction, urine and stool incontinence, states requiring constant care by a third person, epilepsy with frequent seizures.

One of the main advantages of recombinant technology is its ability to produce a consistent product with each subsequent lot. Manufacturing runs have produced ReFacto with specific activity within a consistent range. Additional analyses using peptide mapping, carbohydrate fingerprinting, and other characterization and purity measurements have demonstrated the lot-to-lot consistency of ReFacto.16

The chromogenic substrate assay forms the basis for the potency labeling for ReFacto. Either the chromogenic substrate assay or the one-stage clotting assay for the factor VIII activity levels may be used; however, results of the one-stage clotting assay are lower than those obtained with the chromogenic substrate assay.

Severe depression (melancholia) is the most frequent indication for ECT. Patients with this illness experience sadness and despair, have difficulty concentrating, lose appetite and weight, sleep poorly, blame themselves, are unable to enjoy life, and often think of suicide. Mania and schizophrenia are other illnesses that can be helped by ECT.

The same way there are contra-indications to certain pharmaceuticals (some medecines cannot be associated to other ones), there are contra-indications to the practice of Phosphenism. Similarily, some athletes cannot practice certain sports that would spoil the results they are trying to achieve. For example, boxers will not practice heavy body building as it would spoil their quickness, suppleness and efficiency.

Multiple thoracic compression deformities with decreased thoracic cage threatens pulmonary compromise, impacts appetite, GI function, balance Subacute or acute fractures less than one year old yield greatest results (less than 4-6 months ideal); older fractures can also be treated Radicular pain or radiculopathy caused by a compressive syndrome unrelated to vertebral body collapse

Please consult the product insert that is contained in the product packaging. PDF copies of all ETHEX product inserts are also available on the product pages of the ETHEX website.

Dermagraft is indicated for use in the treatment of full-thickness diabetic foot ulcers greater than 6 weeks duration, which extend through the dermis, but without tendon, muscle, joint capsule, or bone exposure. Dermagraft should be used in conjunction with standard wound care regimens and in patients who have adequate blood supply to the involved foot.

It should be avoided only in case of serious renal disease, hepatic disease or if you have been advised by your doctor to avoid any kind of stimulant.

Patients who have undergone the ileoanal J-pouch surgery and who are troubled by excessive frequent bowel movements or lack of control with soiling themselves. People who have previously undergone a Kock pouch operation and are having difficulties can have it transformed into a Barnett pouch. There are miscellaneous reasons including multiple colon tumors and patients in whom the colon was injured from trauma.

The FemSoft Insert is a new option for the non-surgical management of female stress urinary incontinence (SUI). Results of clinical studies indicate that the FemSoft Insert is a viable option for women with mild to severe SUI due to urethral hypermobility or intrinsic sphincter deficiency (ISD).

I use Prosta-Q in men with chronic pelvic pain syndrome. Synonyms for this condition include nonbacterial chronic prostatitis, prostatodynia, pelvic muscle myalgia and NIH category III prostatitis. I first perform localizing cultures of urine and expressed prostatic secretions (EPS) in all men prior to therapy. I treat and sterilize any infection that is found to localize to the prostate.

Alginates have been shown to be useful in a variety of situation; sloughy wounds which also produce a degree of exudate may be dressed with alginate dressings such as Sorbsan, Tegagen, Kaltostat (or other gel forming polysaccharide dressings). The gel which is formed as these products absorb exudate forms a moist covering over the slough preventing it from drying out.

FotoFacial Treatments are beneficial in the treatment of redness and flushing, sun damage, rosacea, and to smooth skin and reduce pores.